Tempest Therapeutics — Third Quarter 2026 Earnings Summary

Tempest Therapeutics reported a net loss of $3.6 million for the third quarter of 2026, with cash and cash equivalents declining to $0.9 million from $7.7 million at the end of 2025. The company secured exclusive licensing rights to Senlang's CD7-targeted lentiviral in vivo CAR-T platform and its lead candidate TPST-4903, while also advancing its next-generation candidate TPST-4003. To support operations, Tempest completed a private placement raising approximately $2.5 million and entered into an equity line of credit with Lincoln Park Capital Fund for up to $50.0 million. Additionally, the Board of Directors was strengthened by the appointments of Nancy Freda-Smith and John W. Frederick, though the company noted substantial doubt regarding its ability to continue as a going concern due to limited cash reserves.